ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,877 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselAzafaros Switzerland AG
Azafaros Switzerland AG Logo
Verified· 2 sources

Azafaros Switzerland AG

Summary

About the company

The company's core activity is the development and marketing of pharmaceuticals, particularly in the field of rare diseases and oncology. The company is involved in clinical development, regulatory affairs and the distribution of medicines, as well as strategic planning and management of business relationships in the pharmaceutical industry.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered5
Development of drug candidates for lysosomal storage diseases
Development of oral small molecules for lysosomal storage diseases, with a focus on metabolic pathways that affect disease-causing metabolite accumulations.
Nizubaglustat program
Late-stage clinical development program with the active substance nizubaglustat for GM1 and GM2 gangliosidoses and Niemann-Pick type C disease; Phase I, Phase II and Phase III studies.
Clinical studies
Conduct and communication of clinical studies for nizubaglustat, including First-In-Human, RAINBOW, PRONTO, NAVIGATE and PRISMA studies.
Patient information on lysosomal storage diseases
Information on GM1 gangliosidosis, GM2 gangliosidosis and Niemann-Pick type C disease, as well as on lysosomal storage diseases, symptoms and disease mechanisms.
Expanded Access Policy
Policy for expanded access for patients; describes the handling of access to nizubaglustat outside clinical trials.

Knowledge

No knowledge articles yet

Once Azafaros Switzerland AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Azafaros Switzerland AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Azafaros Switzerland AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Azafaros Switzerland AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Dufourstrasse 25
4052 Basel

At a glance

Legal form
Corporation
UID
CHE-493.836.086
Founded
2020 · 6 years
Last commercial register change
June 16, 2025
Employees
21 to 50

Similar companies

3B
3T Biosciences Europe GmbH
Basel
FT
FoRx Therapeutics AG
Basel
EP
Eumedica Pharmaceuticals AG
Basel
SA
Solvias AG
Basel